Briakinumab

Drug Profile

Briakinumab

Alternative Names: A-796874.0; ABT-874; Anti-IL-12/23-antibody-Abbott; BSF 415977; J 695; LU 415977; Ozespa; WAY-165772

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Abbott GmbH & Co. KG
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 12 inhibitors; Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Submission Withdrawal Plaque psoriasis
  • Discontinued Crohn's disease; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 01 Oct 2011 Abbott Laboratories completes a phase III trial in Plaque psoriasis in Canada, Switzerland, USA and the European Union (NCT00626002)
  • 14 Jan 2011 Regulatory submission withdrawn for Plaque psoriasis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top